"The U.S. Food and Drug Administration yesterday approved Ruconest, the first recombinant C1-Esterase Inhibitor product for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE).
Severe hypersensitivity reaction to siltuximab or any of the excipients in SYLVANT.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 4/22/2016
Additional Sylvant Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.